596 related articles for article (PubMed ID: 21618594)
1. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
Mai QG; Zhang ZM; Xu S; Lu M; Zhou RP; Zhao L; Jia CH; Wen ZH; Jin DD; Bai XC
J Cell Biochem; 2011 Oct; 112(10):2902-9. PubMed ID: 21618594
[TBL] [Abstract][Full Text] [Related]
2. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
3. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
5. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells.
Poulsen RC; Wolber FM; Moughan PJ; Kruger MC
Prostaglandins Other Lipid Mediat; 2008 Feb; 85(1-2):42-8. PubMed ID: 18077200
[TBL] [Abstract][Full Text] [Related]
6. Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats.
Charoenphandhu N; Teerapornpuntakit J; Methawasin M; Wongdee K; Thongchote K; Krishnamra N
Can J Physiol Pharmacol; 2008 May; 86(5):240-8. PubMed ID: 18432284
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
8. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
Persson E; Lerner UH
J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
[TBL] [Abstract][Full Text] [Related]
9. Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro.
Yuan SY; Sheng T; Liu LQ; Zhang YL; Liu XM; Ma T; Zheng H; Yan Y; Ishimi Y; Wang XX
Chin J Nat Med; 2016 Apr; 14(4):265-269. PubMed ID: 27114313
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
Yang L; Hai Y; Zhou JL
Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
[TBL] [Abstract][Full Text] [Related]
11. Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet.
Zhang Y; Dong XL; Leung PC; Wong MS
Bone; 2009 Jan; 44(1):46-52. PubMed ID: 18848653
[TBL] [Abstract][Full Text] [Related]
12. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells.
Coetzee M; Haag M; Kruger MC
J Nutr Biochem; 2007 Jan; 18(1):54-63. PubMed ID: 16650751
[TBL] [Abstract][Full Text] [Related]
13. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
14. Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation.
Kühn MC; Willenberg HS; Schott M; Papewalis C; Stumpf U; Flohé S; Scherbaum WA; Schinner S
Mol Cell Endocrinol; 2012 Feb; 349(2):180-8. PubMed ID: 22040599
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
16. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats.
Wang FS; Ko JY; Lin CL; Wu HL; Ke HJ; Tai PJ
Bone; 2007 Feb; 40(2):485-92. PubMed ID: 17055793
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
18. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells.
Wang Y; Li LZ; Zhang YL; Zhu YQ; Wu J; Sun WJ
Mol Cell Endocrinol; 2011 Apr; 337(1-2):43-51. PubMed ID: 21291955
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression.
Brechter AB; Lerner UH
Arthritis Rheum; 2007 Mar; 56(3):910-23. PubMed ID: 17328065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]